Viva Biotech Holdings (Viva Biotech) filed its monthly return for April 2026, confirming that no changes occurred in either authorised or issued share capital during the period.

Authorised capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025, equivalent to total authorised capital of USD 100,000.

The issued share count stayed at 2.13 billion shares, and the company continued to hold zero treasury shares. Consequently, no new shares were issued, cancelled, or repurchased in April, and no capital was raised from equity exercises.

Viva Biotech affirmed compliance with the Hong Kong Stock Exchange’s minimum 25 percent public-float requirement as at 30 April 2026.

Outstanding equity incentives were unchanged: 2.22 million options under the Pre-IPO Share Incentive Schemes and 13.70 million options under the Post-IPO Share Option Scheme, leaving the maximum potential dilution from existing options at 15.92 million shares. No options were granted, exercised, cancelled, or lapsed during the month.

The company reported no warrants, convertible securities, Hong Kong Depositary Receipts, or other equity-linked instruments outstanding or issued in April 2026.